ProAxsis Ltd Announces Financial Success and New Fundraising Initiative

The latest update is out from NetScientific ( (GB:EMVC) ).

ProAxsis Ltd, backed by EMV Capital, reported strong financial and operational progress, with a 92% revenue increase and significant cost reductions. The company is launching a £800,000 fundraising initiative to enhance commercial efforts and profitability, including advancing its COPD clinical study. ProAxsis aims to leverage partnerships with organizations like Imperial College London and Innovate UK to broaden its market reach and accelerate its second-generation NEATstik platform. The fundraising will support core business activities and crucial research developments, positioning ProAxsis for future growth and value creation.

More about NetScientific

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group that supports high-growth companies. It focuses on generating returns from fast-growing sectors and technologies and provides proactive management to advance portfolio companies. ProAxsis Limited, a spin-out from Queens University Belfast, specializes in respiratory diagnostics, offering immunoassays for chronic respiratory diseases and developing point-of-care testing solutions.

YTD Price Performance: -0.21%

Average Trading Volume: 42,827

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £13.47M

For a thorough assessment of EMVC stock, go to TipRanks’ Stock Analysis page.